Laboratory and Epidemiology Communications

Intrafamilial Transmission of a Sabin 1-Related Poliovirus in Shizuoka Prefecture, Japan

Masaaki Sugieda, Satoshi Adachi, Megumi Inayoshi, Takashi Masuda, Munetoshi Tsubota, Hozumi Mano, Masato Iwama, Yoshio Murakami, Hiromu Yoshida, and Hiroyuki Shimizu*

Shizuoka Institute of Environment and Hygiene, Shizuoka 420-8637; Shizuoka Prefectural of Atami Pubic Health Center, Atami 413-0016; Kawana Seaside School Clinic, Ito 414-0044; and Department of Virology II, National Institute of Infectious Diseases, Tokyo 208-0011, Japan

Communicated by Takaji Wakita

(Accepted June 6, 2006)

On June 6, 2005, a 41-year-old male presented with fever (39.0°C) and malaise, and was admitted to a clinic in Shizuoka Prefecture, Japan. Immediately before the onset, the patient had taken care of his 9-month-old daughter, who had diarrhea and who had previously received her first dose of oral poliovirus vaccine (OPV) on May 30, 2005.

To address the possibility of vaccine-associated paralytic poliomyelitis (VAPP) due to intrafamilial poliovirus transmission, clinical samples were collected from the patient and his vaccinated daughter on June 10 for virus isolation and identification. Polioviruses were isolated from a throat swab of the patient and from a stool sample of the daughter in Vero cells (1). Both isolates were identified as a type 1 poliovirus by the microneutralization test (Table 1). Two different methods, which were based on genetic and antigenic approaches and which used PCR-restriction enzyme fragment length polymorphism and Sabin-specific monoclonal antibodies, respectively, were employed for intratypic differentiation (ITD) of polioviruses to distinguish between the vaccine and wild polioviruses (2,3). As shown in Table 1, the ITD assays identified both type 1 poliovirus isolates as Sabin 1-like polioviruses, which were commonly found in the stool samples from healthy OPV recipients and their close contacts (4,5).

During clinical follow-up, the patient and his daughter completely recovered without any sequelae, although intrafamilial transmission of the type 1 OPV strain was epidemiologically suspected. However, another possible VAPP case, that of a 36-year-old male who had a contact infection with type 3 OPV strain from his son, was recently reported in Ehime Prefecture, Japan (6). These incidents revealed the existence of susceptible populations and the risk for VAPP as long as OPV is still used in Japan (7), and provide a strong argument for the introduction of an inactivated poliovirus vaccine instead of OPV to reduce the risk of VAPP, concomitant with routine OPV immunization (8,9). In the meantime, highly qualified disease and laboratory surveillance activities for VAPP are also needed.


REFERENCES

5. Kuramitsu, M., Kuroiwa, C., Yoshida, H., Miyoshi,

<table>
<thead>
<tr>
<th>Virus ID</th>
<th>Sample</th>
<th>Source</th>
<th>Sample</th>
<th>Date of sampling</th>
<th>Serotype</th>
<th>Poliovirus isolate</th>
<th>ITD</th>
<th>PCR-RFLP1)</th>
<th>MoAb2)</th>
<th>Final result</th>
</tr>
</thead>
<tbody>
<tr>
<td>0517</td>
<td>Patient</td>
<td>Throat swab</td>
<td>June 10, 2005</td>
<td>Type 1</td>
<td>Sabin 1</td>
<td>Sabin-like</td>
<td>Sabin 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0518</td>
<td>Daughter</td>
<td>Stool</td>
<td>June 10, 2005</td>
<td>Type 1</td>
<td>Sabin 1</td>
<td>Sabin-like</td>
<td>Sabin 1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1) PCR-restriction enzyme fragment length polymorphism test as a genetic intratypic differentiation (ITD) assay.
2) Neutralization test using Sabin-specific monoclonal antibodies as an antigenic ITD assay.

*Corresponding author: Mailing address: Department of Virology II, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashimurayama, Tokyo 208-0011, Japan. Tel: +81-42-561-0771, Fax: +81-42-561-4729, E-mail: hshimizu@nih.go.jp


